6.50

5.01% 0.31

After Hours: 6.51 0.010 +0.15%

Trevi Therapeutics Inc (TRVI)

Overview News Price History Option Chain Financials Discussions Forecast

Trevi Therapeutics Inc stock is traded at $6.50, with a volume of 1.65M. It is up +5.01% in the last 24 hours and up +6.56% over the past month. Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

Previous Close:

$6.19

Open:

$6.19

24h Volume:

1.65M

Relative Volume:

0.73

Market Cap:

$661.38M

Revenue:

Net Income/Loss:

$-29.07M

P/E Ratio:

-22.41

EPS:

-0.29

Net Cash Flow:

$-31.85M

1W Performance:

-1.52%

1M Performance:

+6.56%

6M Performance:

+136.36%

1Y Performance:

+128.87%

1-Day Range:

$6.19

$6.6999

1-Week Range:

$6.115

$6.83

52-Week Range:

$2.30

$7.39

Trevi Therapeutics Inc Stock (TRVI) Company Profile

Name

Trevi Therapeutics Inc

Sector

Healthcare (1170)

Industry

Biotechnology (671)

Phone

203-304-2499

Address

195 CHURCH STREET, NEW HAVEN, CT

Employee

Twitter

@TreviThera

Next Earnings Date

2025-03-18

Latest SEC Filings

TRVI's Discussions on Twitter

Compare TRVI with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TRVI Trevi Therapeutics Inc	6.50	671.52M	0	-29.07M	-31.85M	-0.29
ONC Beigene Ltd Adr	228.38	25.07B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	438.65	109.14B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.27	36.39M	0	0	0	0.00
REGN Regeneron Pharmaceuticals Inc	594.32	56.98B	14.09B	4.50B	2.96B	39.28
VRNA Verona Pharma Plc Adr	71.31	5.39B	0	-153.72M	-103.81M	-2.00

Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-10-25	Reiterated	Needham	Buy
Mar-10-25	Upgrade	Raymond James	Outperform → Strong Buy
Dec-12-24	Reiterated	H.C. Wainwright	Buy
Sep-09-24	Resumed	Leerink Partners	Outperform
Aug-30-24	Initiated	H.C. Wainwright	Buy
Aug-30-24	Initiated	Raymond James	Outperform
Jun-13-24	Initiated	Rodman & Renshaw	Buy
Apr-12-23	Initiated	B. Riley Securities	Buy
Nov-22-22	Initiated	SVB Leerink	Outperform
Jun-03-19	Initiated	BMO Capital Markets	Outperform
Jun-03-19	Initiated	Needham	Buy
Jun-03-19	Initiated	SVB Leerink	Outperform
Jun-03-19	Initiated	Stifel	Buy

View All

Trevi Therapeutics Inc Stock (TRVI) Latest News

03:48 AM

Dimensional Fund Advisors LP Grows Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

03:48 AM

May 15, 2025

12,000 Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI) Purchased by Raymond James Financial Inc. - Defense World

May 15, 2025

May 14, 2025

Wall Street Analysts See a 195.05% Upside in Trevi Therapeutics (TRVI): Can the Stock Really Move This High? - Yahoo Finance

May 14, 2025

May 13, 2025

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2025 Earnings Call Transcript - Insider Monkey

May 13, 2025

May 11, 2025

Wells Fargo & Company MN Buys 9,562 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

May 11, 2025

Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates - Seeking Alpha

May 11, 2025

May 09, 2025

Trevi Therapeutics Reports Q1 2025 Results and Updates - TipRanks

May 09, 2025

MetLife Investment Management LLC Purchases 19,857 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

May 09, 2025